TRV130

DRUG5 trials

Sponsors

Trevena Inc.

Conditions

Acute PainHealthyPain

Phase 1

Study of the Effects of TRV130, at Therapeutic and Supra Therapeutic Doses, on QTc Intervals

CompletedNCT02344303

Trevena Inc.Healthy

Start: 2014-12-31End: 2015-10-31Updated: 2017-05-12

Phase 2

A Study of TRV130 for the Treatment of Pain After Bunionectomy

CompletedNCT02100748

Trevena Inc.Acute Pain

Start: 2014-04-30End: 2014-10-31Updated: 2020-09-16

A Study of TRV130 for the Treatment of Pain After Abdominoplasty

CompletedNCT02335294

Trevena Inc.Pain

Start: 2014-12-31End: 2015-08-31Updated: 2020-09-16

A Pilot Study of TRV130 for the Treatment of Fracture Pain

TerminatedNCT02520297

Trevena Inc.Pain

Start: 2015-10-20End: 2015-10-23Updated: 2020-09-07

Phase 3

A Open-label Study to Evaluate the Safety of TRV130 in Patients With Acute Pain

CompletedNCT02656875

Trevena Inc.Acute Pain

Start: 2015-12-31End: 2017-08-31Updated: 2020-09-24

Related Papers

<p>ATHENA: A Phase 3, Open-Label Study Of The Safety And Effectiveness Of Oliceridine (TRV130), A G-Protein Selective Agonist At The μ-Opioid Receptor, In Patients With Moderate To Severe Acute Pain Requiring Parenteral Opioid Therapy</p>

Journal of Pain Research2019-11-0164 citations

A randomized, Phase IIb study investigating oliceridine (TRV130), a novel &micro;-receptor G-protein pathway selective (&micro;-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty

Journal of Pain Research2017-10-01143 citations